Skip to main content
Have a personal or library account? Click to login
The Efficacy of Thyrotropin Suppression Therapy in Treatment of Differentiated Thyroid Cancer after Total Thyroidectomy Cover

The Efficacy of Thyrotropin Suppression Therapy in Treatment of Differentiated Thyroid Cancer after Total Thyroidectomy

Forum of Clinical Oncology
Volume 6 (2015): Issue 2 (June 2015)
By:  and    
Open Access
|Jun 2015
References

References

  1. [1] Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the National Population-Based Cancer Registry Program. J Cancer Epidemiol 2014; 2014:437971.
    Open DOISearch in Google Scholar
  2. [2] Sherman SI. Thyroid carcinoma. Lancet 2003; 361(9356):501-511.
    Open DOISearch in Google Scholar
  3. [3] Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998; 83 (12):2638-2648.
    Open DOISearch in Google Scholar
  4. [4] Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB. Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. Surgery 2001; 130 (6): 921-930.
    Open DOISearch in Google Scholar
  5. [5] Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86 (4):1447-1463.
    Open DOISearch in Google Scholar
  6. [6] Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2009; 19(11):1167-1214.
    Open DOISearch in Google Scholar
  7. [7] Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002; 26(8): 879-885.
    Open DOISearch in Google Scholar
  8. [8] Wartofsky L, Van Nostrand D. Radioiodine treatment of well-differentiated thyroid cancer. Endocrine 2012; 42(3): 506-513.
    Open DOISearch in Google Scholar
  9. [9] McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 2002; 34(7-8): 554-564.
    Open DOISearch in Google Scholar
  10. [10] Biondi B, Filetti S, Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 2005; 1: 32-40.
    Open DOISearch in Google Scholar
  11. [11] Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, et al. Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 2012; 172(10):799-809.
    Open DOISearch in Google Scholar
  12. [12] Sugitani I, Fujimoto Y. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study. Surgery 2011; 150(6): 1250-1257.
    Open DOISearch in Google Scholar
  13. [13] Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated thyroid cancer. Thyroid 2010; 20(2):135-146.
    Open DOISearch in Google Scholar
  14. [14] Rongen HA, Hoetelmans RM, Bult A, van Bennekom WP. Chemiluminescence and immunoassays. J Pharm Biomed Anal 1994; 12(4):433-462.
    Open DOISearch in Google Scholar
  15. [15] Koszegi T. Immunoluminometric detection of human procalcitonin. J Biochem Biophys Methods 2002; 53(1-3):157-64.
    Open DOISearch in Google Scholar
  16. [16] Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104: 947-953.
    Search in Google Scholar
  17. [17] Ichikawa Y, Saito E, Abe Y, Homma M, Muraki T. Presence of TSH receptor in thyroid neoplasms. J Clin Endocrinol Metab 1976; 42(2): 395-398.
    Open DOISearch in Google Scholar
  18. [18] Carayon P, Thomas-Morvan C, Castanas E, Tubiana M. Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab 1980; 51(4):915-920.
    Open DOISearch in Google Scholar
  19. [19] Clark OH, Gerend PL, Goretzki P, Nissenson RA. Characterization of the thyrotropin receptoradenylate cyclase system in neoplastic human thyroid tissue. J Clin Endocrinol Metab 1983; 57(1):140-147.
    Open DOISearch in Google Scholar
  20. [20] Roger P, Taton M, Van Sande J, Dumont JE. Mitogenic effects of thyrotropin and adenosine 3’, 5’-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab 1988; 66(6):1158-1165.
    Open DOISearch in Google Scholar
  21. [21] Goretzki PE, Frilling A, Simon D, Roeher HD. Growth regulation of normal thyroids and thyroid tumors in man. Recent Results Cancer Res 1990; 118:48-63.
    Open DOISearch in Google Scholar
  22. [22] Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84(11): 3877-3885.
    Open DOISearch in Google Scholar
  23. [23] Mazzaferri EL, Young RL, Oertel JE, Kemmerer WT, Page CP. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore) 1977; 56(3):171-196.
    Open DOISearch in Google Scholar
  24. [24] Brabant G. Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? J Clin Endocrinol Metab 2008; 93(4): 1167-1169.
    Open DOISearch in Google Scholar
  25. [25] Cooper DS. TSH suppressive therapy: an overview of long-term clinical consequences. Hormones 2010; 9(1):57-59.
    Open DOISearch in Google Scholar
  26. [26] Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81(12):4318-4323.
    Search in Google Scholar
  27. [27] Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998; 8(9):737-744.
    Open DOISearch in Google Scholar
  28. [28] Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006; 16(12):1229-1242.
    Open DOISearch in Google Scholar
  29. [29] Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97 (5): 418-428.
    Open DOISearch in Google Scholar
  30. [30] Lang BH, Chow SM, Lo CY, Law SC, Lam KY. Staging systems for papillary thyroid carcinoma: a study of 2 tertiary referral centers. Ann Surg 2007; 246(1): 114-121.
    Open DOISearch in Google Scholar
  31. [31] Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery 2004; 135(2):139-148.
    Open DOISearch in Google Scholar
  32. [32] Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, Smit JW. Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. J Clin Endocrinol Metab 2007; 92(7): 2610-2615.
    Open DOISearch in Google Scholar
  33. [33] Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992; 164 (6): 658-661.
    Open DOISearch in Google Scholar
  34. [34] Andersen PE, Kinsella J, Loree TR, Shaha AR, Shah JP. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg 1995; 170 (5): 467-470.
    Open DOISearch in Google Scholar
  35. [35] Coburn MC, Wanebo HJ. Prognostic factors and management considerations in patients with cervical metastases of thyroid cancer. Am J Surg 1992; 164 (6): 671-676.
    Open DOISearch in Google Scholar
  36. [36] Voutilainen PE, Multanen MM, Leppäniemi AK, Haglund CH, Haapiainen RK, Franssila KO. Prognosis after lymph node recurrence in papillary thyroid carcinoma depends on age. Thyroid 2001; 11 (10): 953-957.
    Open DOISearch in Google Scholar
  37. [37] Staunton MD. Thyroid cancer. A multivariate analysis on influence of treatment on long-term survival. Eur J Surg Oncol 1994; 20 (6): 613-621. 32 Niveen A. Abo-Touk, Dalia H. Zayed
    Search in Google Scholar
  38. [38] Biondi B, Fazio S, Carella C, Sabatini D, Amato G, Cittadini A, et al. Control of adrenergic overactivity by beta-blockade improves the quality of life in patients receiving long term suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1994; 78(5): 1028-1033.
    Search in Google Scholar
  39. [39] Gullu S, Altuntas F, Dincer I, Erol C, Kamel N. Effects of TSH-suppressive therapy on cardiac morphology and function: beneficial effects of the addition of beta-blockade on diastolic dysfunction. Eur J Endocrinol 2004; 150(5): 655-661.
    Open DOISearch in Google Scholar
  40. [40] Kung AW, Yeung SS. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin. J Clin Endocrinol Metab 1996; 81(3): 1232-1236.
    Search in Google Scholar
DOI: https://doi.org/10.1515/fco-2015-0010 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 24 - 33
Published on: Jun 30, 2015
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Keywords:
Thyroid cancer,
differentiated thyroid cancer,
TSH suppression,
thyroxin therapy
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2015 Niveen A. Abo-Touk, Dalia H. Zayed, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 6 (2015): Issue 2 (June 2015)
Previous article
Next article